Cantex Pharmaceuticals, a Florida-based biotechnology company, has achieved a significant milestone by securing Fast Track designation from the US Food and Drug Administration (FDA) for its innovative acute myeloid leukemia (AML) drug, CX-01. This designation is specifically for the treatment of patients over 60 years old undergoing induction therapy for newly diagnosed AML. CX-01 is […]
Tolero Pharmaceuticals has entered into a clinical research collaboration with AbbVie to explore the potential of combining their respective drugs, alvocidib and venetoclax, for the treatment of relapsed/refractory acute myeloid leukemia (AML). This innovative partnership aims to harness the synergistic effects of these drugs to enhance treatment efficacy in AML, a notoriously difficult-to-treat cancer. Alvocidib, […]
The US Food and Drug Administration (FDA) has granted approval to Agios Pharmaceuticals’ TIBSOVO (ivosidenib) for the treatment of adult patients with acute myeloid leukemia (AML) who have relapsed or refractory conditions and are confirmed to have an isocitrate dehydrogenase-1 (IDH1) mutation. This approval marks a significant advancement in targeted cancer therapy, offering new hope […]